Tumor cell-derived lactic acid inhibits the interaction of PD-L1 protein and PD-L1 antibody in the PD-L1/PD-1 blockade therapy-resistant tumor
W. Oh, A. M. J. Kim, D. Dhawan, D. W. Knapp, S.-O. Lim
This study identifies tumor-derived lactic acid as a factor inhibiting PD-L1 antibody binding, contributing to PD-1/PD-L1 blockade resistance, and proposes a combination therapy to overcome this resistance.
bioRxiv · Aug 4, 2023 · PreprintCancer Biology